Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Gynecologic Oncology

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Obstetrics And Gynecology

Show all topics

DOI

10.1016/j.ygyno.2024.10.022